Report : Middle East and Africa Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)
Treatment Segment to Dominate Middle East & Africa Non-Alcoholic Steatohepatitis market Forecast to 2028 during 2019–2028
According to a new market research study on the Middle East & Africa Non-Alcoholic Steatohepatitis market Forecast to 2028 –– by product, application, sales channel and countries is expected to reach US$ 194.00 million by 2028 from US$ 35.72 million in 2021. The market is estimated to grow at a CAGR of 27.3% from 2021 to 2028. The report provides trends prevailing in the Middle East & Africa Non-Alcoholic Steatohepatitis market along with the drivers and restraints pertaining to the market growth. Rising prevalence of NASH is the major factor driving the growth of the Middle East & Africa Non-Alcoholic Steatohepatitis market. However, issues associated with stringent regulations related to Non-Alcoholic Steatohepatitis the growth of Middle East & Africa Non-Alcoholic Steatohepatitis market.
The Middle East & Africa Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the Middle East & Africa Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others. The ocaliva segment is expected to be the fastest growing segment over the forecaste period. Based on application the Middle East & Africa Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated Middle East & Africa Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the Middle East & Africa Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated Middle East & AfricaNon-Alcoholic Steatohepatitis market in 2020. Based on country, the Middle East & Africa Non-Alcoholic Steatohepatitis market segmented into South Africa,Saudi Arabia,UAE and RoMEA. The South Africa is dominated the Middle East & Africa Non-Alcoholic Steatohepatitis market in 2020.
Cadila Pharmaceutical,Intercept Pharmaceutical,Novartis AG,Galmed Pharmaceutical,GENFIT,Siemens Healthineers AG and Laboratory Corporation of America are among the leading companies in the Middle East & Africa Non-Alcoholic Steatohepatitis market. For instance, Dec-2021 Ipsen and GENFIT have entered a long-term strategic partnership for global collaboration between the two companies. This partnership has given GENFIT a global license to manufacture, develop, and commercialize GENFIT’s investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC). The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in dynamic market.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sales@businessmarketinsights.com